Advisor Group’s Gyre Therapeutics GYRE Stock Holding History

Advisor Group’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-25	Closed	-$1K	–	5321
2019 Q2	$1K	Sell	25 -639	-96%	-$39.9K	﹤0.01%	5106
2019 Q1	$40K	Buy	+664	New	+$42.7K	﹤0.01%	3531

Other funds holding GYRE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Advisor Group's GYRE Position: Q3 2019 in Review

Advisor Group sold out of Gyre Therapeutics (GYRE) in Q3 2019, closing a stake of 25 shares — an estimated $1K sold.

Advisor Group first reported a position in GYRE in Q1 2019 and held it in 2 quarters. The position peaked at $40K in Q1 2019. 42 funds tracked by Wall St. Rank hold GYRE as of Q3 2019.

Advisor Group reported no remaining Gyre Therapeutics position as of Q3 2019 after selling out during the quarter.
Advisor Group sold 25 Gyre Therapeutics shares in Q3 2019, an estimated $1K.
Advisor Group first reported a position in Gyre Therapeutics in Q1 2019 and held it in 2 quarters.
Advisor Group's Gyre Therapeutics position peaked at $40K in Q1 2019.
42 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2019.

Based on Advisor Group's 13F filing for Q3 2019, filed 13 Nov 2019.